REG - Trellus Health PLC - Issue of Equity - Conversion of Loan Notes

Trellus HealthAnnouncement

18/03/2026 12:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260318:nRSR1821Xa&default-theme=true

RNS Number : 1821X  Trellus Health PLC  18 March 2026

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Issue of Equity - Conversion of Loan Notes

 

LONDON, U.K. AND NEW YORK, U.S. (18 March 2026). Trellus Health® plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programs and value-based solutions to manage complex chronic
conditions, announces that further to the Company's announcement on 30
December 2025
(https://www.londonstockexchange.com/news-article/TRLS/proposed-issue-of-secured-convertible-loan-notes/17393494)
and the passing of the relevant resolutions at the General Meeting on 20
January 2026
(https://www.londonstockexchange.com/news-article/TRLS/result-of-meeting/17422249)
, the Company has issued 32,025,278 new Ordinary Shares following the
conversion of £75,000 of the principal amount outstanding under the second
tranche of the Secured Convertible Loan Notes.

 

Accordingly, application has been made to the London Stock Exchange for the
new Ordinary Shares to be admitted to trading on AIM. It is expected that
admission of the 32,025,278 new Ordinary Shares to trading on AIM will become
effective on, or around, 23 March 2026 ("Admission").

 

Total voting rights

Following admission the Company will have 273,637,618 Ordinary Shares in
issue. The Company holds no ordinary shares in treasury. Therefore, the total
number of voting rights in the Company is 273,637,618.

 

This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

Capitalised terms used but not otherwise defined in this announcement shall
have the meanings given to them in the Company's announcement released on 30
December 2025.

 

For further information please contact:

 

 Trellus Health plc                                                  https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder          Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)               Tel: +44 (0)20 7496 3000
 Philip Davies

 Walbrook PR                         Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                     (mailto:trellus@walbrookpr.com)
 Lianne Applegarth / Alice Woodings   +44 (0)7584 391 303 / +44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer
hospitalisations and a reduction of over 70% in emergency room visits. Given
the common emotional and mental health struggles associated with a variety of
chronic conditions, Trellus Health considers its approach to have potential
utility and demand across many conditions.

 

Trellus Health also offers a seamless solution for pharmaceutical partners
from clinical trials to commercialisation, harnessing resilience-based methods
to drive both trial and patient support success by empowering patients to stay
engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both world-leading experts at treating and healing
both the physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEJPMTTMTTBBRF



            Copyright 2019 Regulatory News Service, all rights reserved